Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.

<h4>Objective</h4>Several indices have been proposed to assess disease activity in patients with Systemic Lupus Erythematosus (SLE). Recent studies have showed a prevalence of flare between 28-35.3%, persistently active disease (PAD) between 46%-52% and serologically active clinically qu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fabrizio Conti, Fulvia Ceccarelli, Carlo Perricone, Francesca Miranda, Simona Truglia, Laura Massaro, Viviana Antonella Pacucci, Virginia Conti, Izabella Bartosiewicz, Francesca Romana Spinelli, Cristiano Alessandri, Guido Valesini
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2012
Materias:
R
Q
Acceso en línea:https://doaj.org/article/5c6bbb231ff840d196225f3e74beb90e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5c6bbb231ff840d196225f3e74beb90e
record_format dspace
spelling oai:doaj.org-article:5c6bbb231ff840d196225f3e74beb90e2021-11-18T07:04:28ZFlare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.1932-620310.1371/journal.pone.0045934https://doaj.org/article/5c6bbb231ff840d196225f3e74beb90e2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23029327/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>Several indices have been proposed to assess disease activity in patients with Systemic Lupus Erythematosus (SLE). Recent studies have showed a prevalence of flare between 28-35.3%, persistently active disease (PAD) between 46%-52% and serologically active clinically quiescent (SACQ) disease ranging from 6 to 15%. Our goal was to evaluate the flare, PAD and SACQ rate incidence in a cohort of SLE patients over a 2-year follow-up.<h4>Methods</h4>We evaluated 394 SLE patients. Flare was defined as an increase in SLEDAI-2K score of ≥4 from the previous visit; PAD was defined as a SLEDAI-2K score of ≥4, on >2 consecutive visits; SACQ was defined as at least a 2-year period without clinical activity and with persistent serologic activity.<h4>Results</h4>Among the 95 patients eligible for the analysis in 2009, 7 (7.3%) had ≥1 flare episode, whereas 9 (9.4%) had PAD. Similarly, among the 118 patients selected for the analysis in 2010, 6 (5%) had ≥1 flare episode, whereas 16 (13.5%) had PAD. Only 1/45 patient (2.2%) showed SACQ during the follow-up.<h4>Conclusion</h4>We showed a low incidence of flare, PAD and SACQ in Italian SLE patients compared with previous studies which could be partly explained by ethnic differences.Fabrizio ContiFulvia CeccarelliCarlo PerriconeFrancesca MirandaSimona TrugliaLaura MassaroViviana Antonella PacucciVirginia ContiIzabella BartosiewiczFrancesca Romana SpinelliCristiano AlessandriGuido ValesiniPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 9, p e45934 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Fabrizio Conti
Fulvia Ceccarelli
Carlo Perricone
Francesca Miranda
Simona Truglia
Laura Massaro
Viviana Antonella Pacucci
Virginia Conti
Izabella Bartosiewicz
Francesca Romana Spinelli
Cristiano Alessandri
Guido Valesini
Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
description <h4>Objective</h4>Several indices have been proposed to assess disease activity in patients with Systemic Lupus Erythematosus (SLE). Recent studies have showed a prevalence of flare between 28-35.3%, persistently active disease (PAD) between 46%-52% and serologically active clinically quiescent (SACQ) disease ranging from 6 to 15%. Our goal was to evaluate the flare, PAD and SACQ rate incidence in a cohort of SLE patients over a 2-year follow-up.<h4>Methods</h4>We evaluated 394 SLE patients. Flare was defined as an increase in SLEDAI-2K score of ≥4 from the previous visit; PAD was defined as a SLEDAI-2K score of ≥4, on >2 consecutive visits; SACQ was defined as at least a 2-year period without clinical activity and with persistent serologic activity.<h4>Results</h4>Among the 95 patients eligible for the analysis in 2009, 7 (7.3%) had ≥1 flare episode, whereas 9 (9.4%) had PAD. Similarly, among the 118 patients selected for the analysis in 2010, 6 (5%) had ≥1 flare episode, whereas 16 (13.5%) had PAD. Only 1/45 patient (2.2%) showed SACQ during the follow-up.<h4>Conclusion</h4>We showed a low incidence of flare, PAD and SACQ in Italian SLE patients compared with previous studies which could be partly explained by ethnic differences.
format article
author Fabrizio Conti
Fulvia Ceccarelli
Carlo Perricone
Francesca Miranda
Simona Truglia
Laura Massaro
Viviana Antonella Pacucci
Virginia Conti
Izabella Bartosiewicz
Francesca Romana Spinelli
Cristiano Alessandri
Guido Valesini
author_facet Fabrizio Conti
Fulvia Ceccarelli
Carlo Perricone
Francesca Miranda
Simona Truglia
Laura Massaro
Viviana Antonella Pacucci
Virginia Conti
Izabella Bartosiewicz
Francesca Romana Spinelli
Cristiano Alessandri
Guido Valesini
author_sort Fabrizio Conti
title Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
title_short Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
title_full Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
title_fullStr Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
title_full_unstemmed Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
title_sort flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
publisher Public Library of Science (PLoS)
publishDate 2012
url https://doaj.org/article/5c6bbb231ff840d196225f3e74beb90e
work_keys_str_mv AT fabrizioconti flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
AT fulviaceccarelli flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
AT carloperricone flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
AT francescamiranda flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
AT simonatruglia flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
AT lauramassaro flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
AT vivianaantonellapacucci flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
AT virginiaconti flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
AT izabellabartosiewicz flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
AT francescaromanaspinelli flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
AT cristianoalessandri flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
AT guidovalesini flarepersistentlyactivediseaseandserologicallyactiveclinicallyquiescentdiseaseinsystemiclupuserythematosusa2yearfollowupstudy
_version_ 1718423977985048576